Supapannachart 1999.

Study characteristics
Methods	Single‐centre randomized controlled trial
Participants	Inclusion criteria Birth weight < 1250 g Randomization within first 24 hours Platelet count >60,000/uL Plasma creatinine < 2mg/dL & BUN <30 mg/dL No bleeding diathesis Urine output during 8 hours prior to randomization >0.5 mL/kg/hour Exclusion criteria Major congenital anomalies Suspicion of NEC
Interventions	Active intervention (n = 15) IV Indomethacin 0.2mg/kg initial dose, followed by two doses of 0.1mg/kg each every 12 hours Control (n = 15) IV placebo
Outcomes	Relevant outcomes for this study included Mortality IVH Treatment for symptomatic PDA Surgical PDA ligation CLD NEC
Notes	Primary study location: Ramathibodi Hospital, Bangkok, Thailand Study period: 1 April 1994 to 31 May1 1995 Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation method unspecified.
Allocation concealment (selection bias)	Low risk	Sealed envelope technique used.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All personnel were blinded to group, identical placebo was administered to control
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All personnel were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomized infants accounted for.
Selective reporting (reporting bias)	Unclear risk	Study protocol unavailable. Unclear if any deviations to protocol exist.
Other bias	Low risk	Appears free of other bias.